Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

JNJ 107.21 +0.51 (0.48%)
price chart
Johnson & Johnson to Remove Formaldehyde From Products
Johnson & Johnson, which makes a range of personal care products like baby shampoo, acne cream and antiwrinkle lotion, announced plans Wednesday to remove a host of potentially harmful chemicals, like formaldehyde, from its line of consumer products ...
Johnson & Johnson Pledges To Purge Controversial Chemicals  NPR (blog)
Johnson & Johnson to Remove Formaldehyde, Other Chemicals from Products  TIME
Related articles »  
Johnson & Johnson Announces a Ban on Harmful Chemicals in Products
Johnson & Johnson made the landmark announcement this week that it would ban harmful chemicals from their products. The company has already made the pledge to remove toxic chemicals from its baby products by 2013.
The Real Lesson of Formaldehyde In Baby Shampoo  TIME
Time for companies to pledge to remove dangerous chemicals from products  Fox News
Related articles »  
Berkshire Cuts Johnson & Johnson Stake
Berkshire pared its holdings of Johnson & Johnson (JNJ) by about two-thirds to 10.3 million shares. The world's biggest health- products maker was ordered in April to pay more than $1.1 billion in fines after an Arkansas jury found the firm misled ...
Berkshire Cuts Johnson & Johnson, Adds National Oilwell  Businessweek
Buffett's Berkshire cuts stakes in J&J, Kraft, P&G  MarketWatch
Related articles »  
Johnson & Johnson Eyes China's Baby Market
Johnson & Johnson is rumored to be considering the acquisition of a local baby-care product vendor Shanghai Elsker in China, a move that could strengthen its foothold in the rapidly-growing Chinese baby-care market.
Genmab, Johnson & Johnson agree $1.1 billion cancer deal
Janssen Biotech will make an upfront payment of $55 million for the license and Johnson & Johnson Development Corp would invest 475 million Danish crowns ($80 million) in new Genmab shares, the company said.
J&J grabs Genmab's promising leukemia antibody in $1.1B deal  FierceBiotech
Genmab in potential $1B myeloma drug deal with J&J  Businessweek
Related articles »  
Trials for Alzheimer's Drug Halted After Poor Results
Johnson & Johnson and Pfizer announced on Monday that they were halting development of a closely watched Alzheimer's drug after two clinical trials failed to show that it was effective in patients with mild to moderate forms of the disease.
Pfizer, J&J scrap Alzheimer's studies as drug fails  Reuters
Pfizer, J&J end development of once-promising Alzheimer's drug  The Star-Ledger - NJ.com
Related articles »  
No More Tears: Johnson & Johnson Cleans Up Its Act and Removes Carcinogens
Prompted by growing concerns raised by the Campaign for Safe Cosmetics, Johnson & Johnson makers of Aveeno, Neutrogena, and Johnson's Baby Shampoo, announced today that it will be removing carcinogens and other toxic chemicals from its baby ...
Related articles »  
Johnson & Johnson Still Hates Women With Heavier Than Normal Periods
Last year the internet was in an uproar because Johnson & Johnson discontinued OB Ultra Absorbency tampons. By internet, I mean women's sites, of course.
Johnson & Johnson unit recalls bone putty
The health regulator said certain lots of bone putty made by Johnson & Johnson unit Synthes were recalled as there was potential for the putty to catch fire if it came in contact with electrosurgical cautery systems during surgery.
Synthes recalls bone putty; can catch fire  Bizjournals.com
Related articles »  
Johnson & Johnson loses bid to throw out $258 million Risperdal jury award
Johnson & Johnson lost a bid to have a Louisiana appeals court throw out an award of almost $258 million that a jury ordered it to pay state officials over the marketing of its Risperdal antipsychotic drug.
Here Are The Allegations That Spurred J&J To Pay A $181 Million ...  Business Insider
Johnson Johnson subsidiary to pay record amount to settle off-label ...  Seattle Post Intelligencer (blog)
Related articles »